Research Articles | Page 8 | Aplastic Anemia & MDS International Foundation Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes Apr 2016 Anemia myelodysplastic syndromes (MDS)
Spontaneous remision of aplastic anemia occurring during a pregnancy Aug 2012 Ann Biol Clin (Paris) aplastic anemia
Myelodysplastic syndromes: pathophysiology, clinical and biological features Dec 2015 Ann Biol Clin (Paris) myelodysplastic syndromes (MDS)
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Sep 2013 Ann Hematol myelodysplastic syndromes (MDS)
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide May 2014 Ann Hematol myelodysplastic syndromes (MDS)
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated? Jul 2012 Ann Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Efficacy and safety of deferasirox in myelodysplastic syndromes Feb 2013 Ann Hematol myelodysplastic syndromes (MDS)
Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis Feb 2015 Ann Hematol aplastic anemia
Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II Nov 2016 Ann Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol Aug 2016 Ann Hematol myelodysplastic syndromes (MDS)
Share with addtoany.com.